Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Hypertension"

174 News Found

Abbott unveils new diabetes care formula amid rising global diabetes crisis
News | November 16, 2025

Abbott unveils new diabetes care formula amid rising global diabetes crisis

The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance


AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Clinical Trials | November 12, 2025

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo


AstraZeneca delivers double-digit growth
News | November 10, 2025

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy


Lupin Digital Health launches VITALYFE
Healthcare | October 31, 2025

Lupin Digital Health launches VITALYFE

AI-powered cardiometabolic wellness platform for India’s workforce


Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection
Drug Approval | October 24, 2025

Caplin Steriles receives FDA approval for ANDA Nicardipine Hydrochloride in 0.9% Sodium Chloride injection

Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable


Roche’s AI-based kidney disease algorithm gains European certification
Digitisation | October 06, 2025

Roche’s AI-based kidney disease algorithm gains European certification

The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite


Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Clinical Trials | October 01, 2025

Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial

Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine


Experts highlight critical link between mental well-being and cardiovascular health
Healthcare | September 29, 2025

Experts highlight critical link between mental well-being and cardiovascular health

Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference


Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
News | August 31, 2025

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives